Department of Radiation Oncology, Mayo Clinic, Rochester, MN 55905, USA.
Int J Radiat Oncol Biol Phys. 2011 Jan 1;79(1):143-50. doi: 10.1016/j.ijrobp.2009.10.046. Epub 2010 Apr 13.
To evaluate survival, relapse patterns, and prognostic factors in patients with colorectal cancer relapse treated with curative-intent therapy, including intraoperative electron radiation therapy (IOERT).
From April 1981 through January 2008, 607 patients with recurrent colorectal cancer received IOERT as a component of treatment. IOERT was preceded or followed by external radiation (median dose, 45.5 Gy) in 583 patients (96%). Resection was classified as R0 in 227 (37%), R1 in 224 (37%), and R2 in 156 (26%). The median IOERT dose was 15 Gy (range, 7.5-30 Gy).
Median overall survival was 36 months. Five- and 10-year survival rates were 30% and 16%, respectively. Survival estimates at 5 years were 46%, 27%, and 16% for R0, R1, and R2 resection, respectively. Multivariate analysis revealed that R0 resection, no prior chemotherapy, and more recent treatment (in the second half of the series) were associated with improved survival. The 3-year cumulative incidence of central, local, and distant relapse was 12%, 23%, and 49%, respectively. Central and local relapse were more common in previously irradiated patients and in those with subtotal resection. Toxicity Grade 3 or higher partially attributable to IOERT was observed in 66 patients (11%). Neuropathy was observed in 94 patients (15%) and was more common with IOERT doses exceeding 12.5 Gy.
Long-term survival and disease control was achievable in patients with locally recurrent colorectal cancer. Continued evaluation of curative-intent, combined-modality therapy that includes IOERT is warranted in this high-risk population.
评估接受以治愈为目的治疗的结直肠癌复发患者的生存、复发模式和预后因素,包括术中电子放射治疗(IOERT)。
从 1981 年 4 月至 2008 年 1 月,607 例复发性结直肠癌患者接受 IOERT 作为治疗的一部分。在 583 例患者(96%)中,IOERT 之前或之后进行了外部放射治疗(中位剂量 45.5 Gy)。切除分为 R0 级 227 例(37%)、R1 级 224 例(37%)和 R2 级 156 例(26%)。IOERT 中位剂量为 15 Gy(范围 7.5-30 Gy)。
中位总生存期为 36 个月。5 年和 10 年生存率分别为 30%和 16%。R0、R1 和 R2 切除的 5 年生存率估计分别为 46%、27%和 16%。多变量分析显示,R0 切除、无前期化疗和最近治疗(在该系列的后半部分)与改善生存有关。中心、局部和远处复发的 3 年累积发生率分别为 12%、23%和 49%。中央和局部复发在以前接受过放疗的患者和接受过部分切除术的患者中更为常见。与 IOERT 部分相关的 3 级或以上毒性在 66 例患者(11%)中观察到。94 例患者(15%)出现神经病变,IOERT 剂量超过 12.5 Gy 时更为常见。
局部复发性结直肠癌患者可实现长期生存和疾病控制。在这一高危人群中,需要继续评估包括 IOERT 在内的以治愈为目的的联合治疗。